Experimental: Phase 1 (SAD Cohorts)
Phase 1 comprises of randomized healthy adult subjects in 4 cohorts. 10 subjects will be randomized at 7:3 (active and placebo) in sequential order in 4 dose escalating cohorts. Each cohort is composed of 2 sentinel subjects randomized at 1:1 (active and placebo), followed by 8 additional subjects randomized at 3:1 (active and placebo).
BMF-219 is an orally bioavailable, covalent small-molecule menin inhibitor.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.